Puma Biotechnology (PBYI) Treasury Shares (2014 - 2026)
Puma Biotechnology's (PBYI) quarterly Treasury Shares came in at $2.0 million in Q1 2026, up 8.63% YoY from $1.9 million in Q1 2025, and up 51.17% on a QoQ basis from $1.3 million in Q4 2025.
Puma Biotechnology (PBYI) Treasury Shares (2014 - 2026) Analysis & Trends
Puma Biotechnology (PBYI) has 13 years of Treasury Shares data on file, last reported at $2.0 million in Q1 2026.
- Quarterly Treasury Shares rose 8.63% year-over-year to $2.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $2.0 million (up 8.63% YoY) and the FY2025 annual result came in at $1.3 million, up 3.53% from the prior year.
- Treasury Shares advanced to $2.0 million in Q1 2026, from $1.3 million in the prior quarter.
- In the past five years, Treasury Shares ranged from a high of $2.4 million in Q1 2023 to a low of $1.3 million in Q4 2024.
- A 5-year average of $1.8 million and a median of $1.8 million in 2025 frame the typical range for Treasury Shares.
- Annual changes were most pronounced in 2023 — Treasury Shares rose 24.33% — and 2024, when it dropped 22.69%.
- Tracing PBYI's Treasury Shares over 5 years: stood at $1.5 million in 2022, then grew by 8.2% to $1.6 million in 2023, then fell by 20.65% to $1.3 million in 2024, then climbed by 3.53% to $1.3 million in 2025, then soared by 51.17% to $2.0 million in 2026.
- The last three Treasury Shares figures came in at $2.0 million (Q1 2026), $1.3 million (Q4 2025), and $1.4 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Treasury Shares (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 36.40 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 5.08 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | - |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 2.72 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | - |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 92,219.00 |
| 10 | Puma Biotechnology | 451.24 Mn | 357.33 Mn | 44.03 Mn | 2.05 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 2.05 Mn |
| Jun 30, 2026 | 2.05 Mn |
| Mar 31, 2026 | 2.02 Mn |
| Mar 31, 2026 | 2.02 Mn |
| Dec 31, 2025 | 1.33 Mn |
| Dec 31, 2025 | 1.33 Mn |
| Sep 30, 2025 | 1.36 Mn |
| Sep 30, 2025 | 1.36 Mn |
| Jun 30, 2025 | 1.81 Mn |
| Jun 30, 2025 | 1.81 Mn |
| Mar 31, 2025 | 1.86 Mn |
| Mar 31, 2025 | 1.86 Mn |
| Dec 31, 2024 | 1.29 Mn |
| Dec 31, 2024 | 1.29 Mn |
| Sep 30, 2024 | 1.37 Mn |
| Sep 30, 2024 | 1.37 Mn |
| Jun 30, 2024 | 1.94 Mn |
| Jun 30, 2024 | 1.94 Mn |
| Mar 31, 2024 | 2.09 Mn |
| Mar 31, 2024 | 2.09 Mn |